Shilpa Medicare and Gilead Sciences have inked pact with United Nations-backed Medicines Patent Pool by entering into agreement to increase the access to medicines for HIV/AIDS treatment. With this initiative, the company will be able to produce five key HIV medicines for sale in over 100 countries depending on the medicine.
As per the agreement, the Karnataka-based firm can produce tenofovir, emtricitabine, cobicistat, elvitegravir and a combination of the four known as -the Quad. For this it will pay 3-5% royalty to the patent-holder Gilead, depending on the medicine.
